Latest news
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingViewTradingView · Fri, 07 Aug 2026 18:31:00 GMTDenali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingViewTradingView · Fri, 07 Aug 2026 14:20:14 GMTDenali Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 12:30:00 GMTDenali Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:DNLI) 2026-08-07 - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 07:25:06 GMTDenali Therapeutics Q2 Earnings Call Highlights - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 01:03:00 GMTDenali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 22:45:12 GMTDenali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 21:40:05 GMTDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:01:33 GMT